Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Am J Clin Oncol. 2009 Dec;32(6):582-6. doi: 10.1097/COC.0b013e3181967f09.

Angiosarcoma of the breast: a rare clinicopathological entity.

Author information

  • 1Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave., Box 647, Rochester, NY 14642, USA. tithipodder@yahoo.com

Abstract

OBJECTIVES:

Angiosarcoma is a rare subtype of sarcoma that usually arises after radiation therapy for primary breast cancer. Primary sarcomas of the breast are rare entities and account for less than 1% of all malignant breast neoplasms. We examine our institutional experience with angiosarcomas of the breast that were diagnosed and treated between 1996 and 2007.

METHODS:

To conduct a retrospective review, all female patients with a diagnosis of angiosarcoma of the breast were identified from our pathology database. Their hospital records were retrieved to gather information on treatment, tumor response, failure, and survival.

RESULTS:

A total of 8 patients were identified who had a histologically confirmed diagnosis of angiosarcoma of the breast. Median age was 70.3 years at diagnosis (range, 35.6-85.7 years). Seven (87%) patients had a history of prior radiation to the breast, whereas 1 (13%) had primary angiosarcoma. The median overall survival was 37.4 months (8.7-92.8 months) and relapse-free survival was 17.9 months (2.5-69.4 months).

CONCLUSIONS:

Even though angiosarcomas are rare neoplasms, they are increasingly recognized as the result of more breast-conserving therapy. High clinical suspicion and MRI may contribute to early diagnosis but a biopsy is always necessary to confirm it. These tumors tend to behave aggressively and require a multidisciplinary approach to improve the outcome.

PMID:
19581792
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk